<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096364</url>
  </required_header>
  <id_info>
    <org_study_id>AK111-201</org_study_id>
    <nct_id>NCT05096364</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis</brief_title>
  <official_title>A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical study&#xD;
      to evaluate the efficacy and safety of AK111 for the treatment of moderate to severe plaque&#xD;
      psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical study&#xD;
      to evaluate the efficacy and safety of AK111 in subjects with moderate to severe plaque&#xD;
      psoriasis. The study will consist of 4 periods: up to 4 weeks screening period, 12 weeks&#xD;
      placebo-controlled period,12 weeks crossover treatment period,44 weeks long-term treatment&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve Psoriasis Area and Severity Index (PASI) 90 response or higher at week 12</measure>
    <time_frame>At week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve PASI 75 response or higher at week 12</measure>
    <time_frame>At week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve static Physician Global Assessment (sPGA) 0 or 1 at week 12</measure>
    <time_frame>At week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve PASI 50, PASI 75, PASI 90 and PASI 100 response up to 68 weeks</measure>
    <time_frame>Baseline to week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AK111 concentrations in serum at different time points</measure>
    <time_frame>Baseline to week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and proportion of subjects who developed anti-drug antibodies (ADAs)</measure>
    <time_frame>Baseline to week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum IL-17A level (Pharmacodynamics parameter）</measure>
    <time_frame>Baseline to week 68</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)/serious adverse events (SAEs)</measure>
    <time_frame>Baseline to week 68</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>AK111 Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK111 Regimen 1 - subcutaneous injection every 4 weeks up to 60 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK111 Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK111 Regimen 2 - subcutaneous injection every 4 weeks up to 60 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK111 Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK111 Regimen 3 - subcutaneous injection every 4 weeks up to 60 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AK111 Regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK111 Regimen 4 - subcutaneous injection every 4 weeks up to 60 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to AK111</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to AK111-Placebo subcutaneous injection, then 1:1 randomized to AK111 Regimen 3 or Regimen 4 at week 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK111/Placebo</intervention_name>
    <description>After loading dose, investigational drug was administered subcutaneously up to 60 weeks.</description>
    <arm_group_label>AK111 Regimen 1</arm_group_label>
    <arm_group_label>AK111 Regimen 2</arm_group_label>
    <arm_group_label>AK111 Regimen 3</arm_group_label>
    <arm_group_label>AK111 Regimen 4</arm_group_label>
    <arm_group_label>Placebo to AK111</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 18 to 75 years of age&#xD;
&#xD;
          2. Moderate to severe plaque-type psoriasis diagnosed for at least 6 months&#xD;
&#xD;
          3. Moderate-to-severe plaque psoriasis as defined at baseline by meeting all three&#xD;
             criteria:&#xD;
&#xD;
               1. Clinical diagnosis of stable plaque psoriasis with involvement of ≥ 10% body&#xD;
                  surface area.&#xD;
&#xD;
               2. Psoriasis area and severity index(PASI) ≥12.&#xD;
&#xD;
               3. Static Physicians Global Assessment score ≥3.&#xD;
&#xD;
          4. Subjects with a history of an inadequate response, intolerable or medically&#xD;
             inappropriate use of systemic therapy and/or phototherapy.&#xD;
&#xD;
          5. Subjects who are women of childbearing potential must have a negative urine pregnancy&#xD;
             test at screening and must be practicing an adequate, medically acceptable method of&#xD;
             birth control for at least 8 months after the last study drug administration.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Forms of psoriasis other than chronic plaque-type psoriasis.&#xD;
&#xD;
          2. History or evidence of active TB, Patients with evidence of latent tuberculosis may&#xD;
             enter the trial after sufficient treatment according to protocol.&#xD;
&#xD;
          3. Positive results of confirmatory serology test for hepatitis B, hepatitis C, HIV or&#xD;
             syphilis at screening.&#xD;
&#xD;
          4. History of a serious or systemic infection within 2 months before screening.&#xD;
&#xD;
          5. History of malignancy of any organ system within the past 5 years.&#xD;
&#xD;
          6. Inadequate washout period for prior drug therapy.&#xD;
&#xD;
          7. Previous use of secukinumab, ixekizumab or any other drug that targets IL-17 or IL-17&#xD;
             receptor.&#xD;
&#xD;
          8. Any medical conditions, in the opinion of the Investigator or the Sponsor's medical&#xD;
             monitor, would place the subject at risk, interfere with study participation or study&#xD;
             results interpretation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1011</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1009</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1016</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1003</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1007</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1012</name>
      <address>
        <city>Chengde</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1018</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1008</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1013</name>
      <address>
        <city>Yancheng</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1001</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1010</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1002</name>
      <address>
        <city>Hanzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AkesoBio Investigative Site 1006</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AK111</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

